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158 AKT1 CONTRIBUTES TO CHONDROCYTE CALCIFICATION
DURING ENDOCHONDRAL OSSIFICATION
A. Fukai, N. Kawamura, K. Nakamura, U.I. Chung, H. Kawaguchi. The
University of Tokyo, Tokyo, JAPAN
Purpose: Endochondral ossiﬁcation plays crucial roles in skeletal dis-
orders like osteoarthritis as well as in skeletal growth. Since the
phosphoinositide-dependent serine-threonine protein kinase Akt has
been proposed to be a pivotal signaling molecule for several factors regu-
lating cartilage metabolism, this study examined the possible involvement
of Akt in the processes of endochondral ossiﬁcation.
Methods: Expressions of the three isoforms of Akt (Akt1, 2 & 3) were
examined by real-time RT-PCR in chondrocytes derived from ribs of
neonatal mice. To know the physiological function of Akt1, we compared
the skeletal phenotypes of homozygous Akt1-deﬁcient (Akt1−/−) mice
with those of the wild-type littermates by plain radiograph, 3D-mCT, and
histological analyses including toluidine blue, von Kossa stainings, type X
collagen (COL10) immunostaining, and BrdU labeling. For gain- and loss-
of-function analyses, we established stable lines of mouse chondrogenic
ATDC5 cells with retroviral overexpression of constitutively active Akt1
(CA-Akt1) and small interfering RNA (siRNA) of Akt1, respectively, and
compared the functions with respective empty-vector controls. Cell pro-
liferation was assessed by CCK-8 assay. The differentiation was deter-
mined by Alcian blue and alkaline phosphatase (ALP) stainings under the
stimulation of insulin. The hypertrophic differentiation was determined by
luciferase assays using ATDC5 cells transfected with a luciferase-reporter
gene construct containing a 4.5-kb fragment of the COL10 promoter.
Calciﬁcation was assessed by Alizarin red staining under the stimulation
of insulin and inorganic phosphate ion (Pi). Expressions of inorganic
pyrophosphate (PPi)-related factors were determined by semi-quantitative
RT-PCR.
Results: Since Akt1 was most highly expressed in chondrocytes among
the three isoforms, we generated Akt1−/− mice and examined the skeletal
phenotype. The Akt1−/− mice exhibited dwarﬁsm with about 20% shorter
limbs and trunks than the wild-type littermates during observation periods
from embryos to 12 weeks postnatal. The entire width and columnar
structure of the growth plate cartilage were normal, and BrdU-positive
proliferative zone and COL10-positive hypertrophic zones were also
unaffected by the Akt1 deﬁciency. However, the width of the calciﬁed
layer and the number of calciﬁed chondrocytes determined by the von
Kossa staining were signiﬁcantly decreased at the bottom of the Akt1−/−
growth plate. In the ATDC5 cell culture, neither the CA-Akt1 nor the
Akt1 siRNA overexpression altered cell proliferation, differentiation, or the
COL10 promoter activity. Contrarily, calciﬁcation of ATDC5 cells cultured
in the presence of insulin/Pi was signiﬁcantly enhanced by the CA-Akt1
and suppressed by the Akt1 si-RNA. These in vivo and in vitro ﬁndings
demonstrate that Akt1 is essential for chondrocyte calciﬁcation without
affecting the prior processes of endochondral ossiﬁcation. As PPi has
been known to be a crucial regulator of chondrocyte calciﬁcation, we
ﬁnally examined expressions of principal modulators of PPi: ANK, NPP1
and Pit1. Although all increased during chondrocyte calciﬁcation under
the insulin/Pi stimulation, none of them was affected by the CA-Akt1 or
the Akt1 si-RNA.
Conclusions: Akt1 controls skeletal growth by maintaining chondrocyte
calciﬁcation during endochondral ossiﬁcation, without affecting the pro-
liferation or differentiation of chondrocytes. Further understanding of the
molecular network related to Akt1, probably independent of the putative
PPi pathway, will quite probably lead to a breakthrough for the treatment
of skeletal disorders like osteoarthritis.
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Purpose: IKKa, one of the two NF-úB activating kinases, has as yet
unknown roles in cartilage pathophysiology. Our previous work revealed
an unexpected role of IKKa in ECM remodelling and progression to hyper-
trophy and terminal differentiation of primary osteoarthritic chondrocytes,
with a “chondrogenic” and abundant ECM being a key feature of cells
lacking IKKa. Here we have begun to mechanistically deﬁne how IKKa
affects the terminal chondrogenic differentiation program.
Methods: Primary chondrocytes were derived from 14 Osteoarthritis
(OA) patients undergoing joint arthroplasty. Stable and efﬁcient expres-
sion of IKKa or IKKb or MMP-13 shRNAs was achieved by transduction
with a pSUPER retroviral vector and populations of shRNA expressing
cells were selected for puromycin resistance. Knock-down (KD) efﬁcien-
cies were determined as follows: by Western blotting for each IKK in
comparison to cells transduced by a ﬁreﬂy luciferase shRNA retrovector;
and by ELISA for MMP-13 released by Il-1b stimulation of monolayer or
micromasses established from MMP-13 KD or control chondrocytes.
High density monolayer and micromass cultures (1, 2 and 3 weeks)
in mineralizing conditions were selected to investigate the effects of
either IKK or MMP-13 KD on key regulators of chondrogenesis (including
SOX-9, Runx-2 and b-catenin), and of angiogenesis (VEGF) at the protein
(immunohistochemistry or western blot) and RNA (real time PCR) levels.
The viability and subcellular features of micromass chondrocytes were
also evaluated to assess their progression to terminal differentiation. ECM
turnover was assessed by comparison of the C1,2C and TIMP staining
of micromasses evaluated by immunohistochemistry.
Results: MMP-13 KD was found to mimick the effects of IKKa KD in the
control of the chondrogenic program, as recapitulated in micromass cul-
tures. Thus loss of either IKKa or MMP-13 suppressed the accumulations
of SOX-9, Runx-2 and VEGF (at the protein and RNA levels) contributing
to the maturational arrest of articular chondrocytes. On the other hand,
in control micromasses, the chondrogenic program progressed up to the
calcium deposition stage in conjunction with reduced cell viability, scant
ECM and a paucity of specialized cell-cell and cell-ECM junctions. IKKa,
IKKb and MMP-13 KD cells also displayed a lower C1,2C staining at
1 week, compared to control micromasses. Noteworthy IKKa KD cells
were markedly and reproducibly characterized by a high level of TIMP-3
staining in 1 week micromasses, while TIMP-1 and TIMP-4 levels were
elevated in some but not in all IKKa samples derived from different OA
patients.
Conclusions: Since micromasses established with IKKa and MMP-13
(the key collagenolitic enzyme in OA) KD chondrocytes, presented com-
parable phenotypes, our data reveal that ECM remodelling has a crucial
role in the capacity of OA chondrocytes to progress towards terminal dif-
ferentiation. Moreover, our observations also suggest that IKKa functions
at least in part as a positive effector of ECM remodelling by suppressing
TIMP-3 (given the unique attributes of TIMP-3 to control MMPs, as well
as ADAMTS-4, 5 and 17), thereby allowing for progression to hypertrophy
in Osteoarthritis and possibly also in normal bone development.
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Purpose: In view of the fact that pathogenesis of osteoarthritis (OA)
involves both the bone and cartilage compartments of the affected joints,
an increasing amount of attention is directed to potential treatments of
OA with positive effect on calcium metabolism. One of the factors that
are known to have an anabolic effect on bone is parathyroid hormone
(PTH). However, in vivo effects of PTH on cartilage has until now been an
open question. In bone, PTH acts on osteoblasts, initiating the G-coupled
receptor pathway through cAMP. Interestingly, cAMP has recently been
shown to be of major importance for the chondrocyte phenotype. Since
chondrocytes and osteoblasts originate from the same mesenchymal
lineage, we hypothesize that chondrocytes and osteoblasts, respond an-
abolically similar to PTH treatment. Thus, PTH could potentially represent
a novel treatment opportunity for OA. To test this hypothesis, we used
validated human OA cartilage in vitro models and a pre-clinical model of
accelerated cartilage loss in vivo for our investigations.
Methods: In vitro: Human chondrocytes were isolated and maintained
serum-free for 1 hour in the presence of 100 mM IBMX (PDE inhibitor), and
subsequently stimulated with PTH 1nM-100 nM + IBMX and the cAMP
levels were quantiﬁed by ELISA. In addition, articular cartilage explants
were cultured in 6 replicates for 17 days, with or without 10 nM PTH
treatment, and 5mCi 35sulphate was added for the last 24 hours. Soluble
proteoglycans were released by 4M GuHCl and incorporated sulphate
was measured. Neo-epitopes of pro-peptides of collagen type II (PIINP)
were quantiﬁed as a measure of formation in the conditioned medium.
In vivo: Thirty 5-month old female rats were subjected to either sham
